134 related articles for article (PubMed ID: 33216964)
1. Relevance of sun safety in patients commencing crizotinib for non-small cell lung cancer.
Heynemann S; Mitchell P
Australas J Dermatol; 2021 May; 62(2):e332-e333. PubMed ID: 33216964
[No Abstract] [Full Text] [Related]
2. Crizotinib-induced lichenoid drug eruption in a patient with lung cancer.
Ho YH; Chen CL
Cutis; 2018 Dec; 102(6):403-406. PubMed ID: 30657798
[TBL] [Abstract][Full Text] [Related]
3. Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib.
Gemma A; Kusumoto M; Kurihara Y; Masuda N; Banno S; Endo Y; Houzawa H; Ueno N; Ohki E; Yoshimura A
J Thorac Oncol; 2019 Apr; 14(4):672-682. PubMed ID: 30521972
[TBL] [Abstract][Full Text] [Related]
4. Renal Injury during Long-Term Crizotinib Therapy.
Yasuma T; Kobayashi T; D'Alessandro-Gabazza CN; Fujimoto H; Ito K; Nishii Y; Nishihama K; Baffour Tonto P; Takeshita A; Toda M; Gabazza EC; Taguchi O; Yonemura S; Hataji O
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257437
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
6. Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.
Ji J; Mitra A; Camidge DR; Riess JW
Clin Lung Cancer; 2021 Nov; 22(6):e851-e855. PubMed ID: 34059475
[No Abstract] [Full Text] [Related]
7. Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report.
Wu S; Liu K; Ren F; Zheng D; Pan D
BMC Pulm Med; 2018 Jul; 18(1):121. PubMed ID: 30029601
[TBL] [Abstract][Full Text] [Related]
8. Development of Complex Hepatic Cysts Is a Potential Side Effect of Crizotinib.
Zaheed M; Bray VJ; Itchins M; Storer P; Kao S
J Thorac Oncol; 2018 Apr; 13(4):e62-e64. PubMed ID: 29576299
[No Abstract] [Full Text] [Related]
9. Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer.
Tereso A; Carreto L; Baptista M; Almeida MA
Acta Med Port; 2019 Mar; 32(3):236-239. PubMed ID: 30946796
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC.
Weber D; Decker M; Schuster M; Folz S; Stürmer CJ; Lutz MP
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3769-3771. PubMed ID: 34373943
[TBL] [Abstract][Full Text] [Related]
11. Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer.
Deng H; Li B; Li L; Peng J; Lv T; Liu Y; Ding C
Pathol Res Pract; 2019 Dec; 215(12):152695. PubMed ID: 31699471
[TBL] [Abstract][Full Text] [Related]
12. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
[TBL] [Abstract][Full Text] [Related]
13. Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients.
Xin S; Fang W; Li J; Li D; Wang C; Huang Q; Huang M; Zhuang W; Wang X; Chen L
J Cancer Res Clin Oncol; 2021 Mar; 147(3):725-737. PubMed ID: 33387041
[TBL] [Abstract][Full Text] [Related]
14. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
15. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S
J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660
[TBL] [Abstract][Full Text] [Related]
16. Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
Schrock AB; Lai A; Ali SM; Miller VA; Raez LE
J Thorac Oncol; 2017 Jul; 12(7):e89-e90. PubMed ID: 28629543
[No Abstract] [Full Text] [Related]
17. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer.
Bland AR; Bower RL; Nimick M; Hawkins BC; Rosengren RJ; Ashton JC
Eur J Pharmacol; 2019 Dec; 865():172749. PubMed ID: 31654622
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and Safety of Crizotinib in Advanced or Recurrent
ALK-positive Non-small Cell Lung Cancer].
Li X; Xu H; Gao F; Kang X; Zhang J; Zhao J; Lin Y; Liu X
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):488-493. PubMed ID: 31451138
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
Brosnan EM; Weickhardt AJ; Lu X; Maxon DA; Barón AE; Chonchol M; Camidge DR
Cancer; 2014 Mar; 120(5):664-74. PubMed ID: 24258622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]